Analysts predict that Lion Biotechnologies, Inc. (NASDAQ:IOVA) will post ($0.35) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Lion Biotechnologies’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.29). Lion Biotechnologies posted earnings per share of ($0.17) in the same quarter last year, which would indicate a negative year over year growth rate of 105.9%. The company is scheduled to issue its next quarterly earnings results on Friday, November 3rd.

According to Zacks, analysts expect that Lion Biotechnologies will report full-year earnings of ($1.42) per share for the current financial year, with EPS estimates ranging from ($1.48) to ($1.30). For the next fiscal year, analysts forecast that the business will report earnings of ($1.47) per share, with EPS estimates ranging from ($1.66) to ($1.23). Zacks’ EPS averages are an average based on a survey of sell-side analysts that cover Lion Biotechnologies.

A number of analysts recently weighed in on the company. Zacks Investment Research upgraded Lion Biotechnologies from a “sell” rating to a “hold” rating in a research report on Tuesday, May 23rd. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Lion Biotechnologies in a research report on Wednesday, June 7th. Cowen and Company restated a “buy” rating on shares of Lion Biotechnologies in a research report on Tuesday, June 6th. FBR & Co restated a “buy” rating on shares of Lion Biotechnologies in a research report on Thursday, May 18th. Finally, Rodman & Renshaw assumed coverage on Lion Biotechnologies in a research report on Wednesday, May 10th. They issued a “buy” rating and a $13.00 target price for the company. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Lion Biotechnologies presently has an average rating of “Buy” and a consensus price target of $13.88.

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in Lion Biotechnologies in the second quarter valued at approximately $103,000. Parametric Portfolio Associates LLC bought a new stake in Lion Biotechnologies in the second quarter valued at approximately $125,000. People s United Financial Inc. bought a new stake in Lion Biotechnologies in the second quarter valued at approximately $143,000. Voya Investment Management LLC bought a new stake in Lion Biotechnologies in the second quarter valued at approximately $208,000. Finally, ProShare Advisors LLC bought a new stake in Lion Biotechnologies in the second quarter valued at approximately $270,000. Hedge funds and other institutional investors own 76.00% of the company’s stock.

Lion Biotechnologies (NASDAQ:IOVA) traded up 4.35% during midday trading on Monday, reaching $6.00. 1,507,385 shares of the company’s stock traded hands. Lion Biotechnologies has a 52-week low of $4.45 and a 52-week high of $8.61. The company’s market cap is $376.12 million. The stock has a 50-day moving average of $5.59 and a 200 day moving average of $6.45.

ILLEGAL ACTIVITY NOTICE: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/04/zacks-brokerages-expect-lion-biotechnologies-inc-iova-to-post-0-35-earnings-per-share.html.

About Lion Biotechnologies

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Get a free copy of the Zacks research report on Lion Biotechnologies (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related stocks with our FREE daily email newsletter.